This leads us to hypothesize that the liver specific induction of G6pc could be responsible for the hyperglycemia that is often observed accompanying TR agonism and may explain why, in this study, treatment with low-dose GC-1 or KB2115 failed to improve hepatic insulin sensitivity (Fig 4D) despite substantially reducing hepatic lipid burden. Here, G6PC1 is linked to Hyperglycemia.